Quick Search:

uzh logo
Browse by:
bullet
bullet
bullet
bullet

Zurich Open Repository and Archive 

Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-40786

Borsig, L (2010). Heparin as an inhibitor of cancer progression. Progress in Molecular Biology and Translational Science, 93:335-349.

[img]
Preview
Accepted Version
PDF
136kB

Abstract

Heparin is frequently used for treatment of cancer-associated thromboembolism. Accumulating clinical evidence indicates that cancer patients treated with unfractionated and low-molecular weight heparin survives longer that patients treated by other anticoagulants, especially patients in the early stage of a disease. Experimental analysis from a number of animal models constantly provides evidence about the ability of heparin to attenuate metastasis. The non-anticoagulant activity of heparin on metastasis includes the ability to inhibit cell-cell-interaction through blocking of P- and L-selectin, to inhibit extracellular matrix protease-heparanase, and to inhibit angiogenesis. This chapter summarizes the current experimental evidence on the biology of heparin during cancer progression with the focus on potential mechanism of heparin antimetastatic activity.

Item Type:Journal Article, refereed, further contribution
Communities & Collections:04 Faculty of Medicine > Institute of Physiology
07 Faculty of Science > Institute of Physiology
DDC:570 Life sciences; biology
Language:English
Date:21 September 2010
Deposited On:21 Jan 2011 11:07
Last Modified:28 Dec 2013 21:39
Publisher:Elsevier
ISSN:1877-1173
Publisher DOI:10.1016/S1877-1173(10)93014-7
PubMed ID:20807651
Citations:Web of Science®. Times Cited: 11
Google Scholar™
Scopus®. Citation Count: 16

Users (please log in): suggest update or correction for this item

Repository Staff Only: item control page